Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

about

Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A

P2860

Q58766034-FD3ED731-4F6C-441A-9792-1F32172BA572

P2860

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Item

http://www.wikidata.org/entity/Q47143892

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@en

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@nl

type

Item

label

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@en

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@nl

prefLabel

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@en

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@nl

P1476

Melanoma Therapeutic Strategie ...... iven Evolutionary Convergence.

@en

P2093

Anniefer N Magpusao

http://www.w3.org/2001/XMLSchema#string

Dennie T Frederick

http://www.w3.org/2001/XMLSchema#string

Drew J Adams

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Stein

http://www.w3.org/2001/XMLSchema#string

Elizabeth Tsui

http://www.w3.org/2001/XMLSchema#string

Genevieve M Boland

http://www.w3.org/2001/XMLSchema#string

Haley E Manchester

http://www.w3.org/2001/XMLSchema#string

Jason W Locasale

http://www.w3.org/2001/XMLSchema#string

Jennifer P Tingley

http://www.w3.org/2001/XMLSchema#string

Karen Cichowski

http://www.w3.org/2001/XMLSchema#string

P2860

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets

MYC, Metabolism, and Cancer

Universes collide: combining immunotherapy with targeted therapy for cancer

Serine, glycine and one-carbon units: cancer metabolism in full circle

Synthetic lethal screens as a means to understand and treat MYC-driven cancers

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Elucidating distinct roles for NF1 in melanomagenesis

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

P304

2796-2812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2017.11.022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meenhard Herlyn

Clemens Krepler

Keith Flaherty

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212027

http://www.w3.org/2001/XMLSchema#string

P932

5728698

http://www.w3.org/2001/XMLSchema#string

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

about

P2860

P2860

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932